These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1089 related articles for article (PubMed ID: 32376954)
21. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
22. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]
23. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987 [TBL] [Abstract][Full Text] [Related]
24. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. Wirth M; Bejanin A; La Joie R; Arenaza-Urquijo EM; Gonneaud J; Landeau B; Perrotin A; Mézenge F; de La Sayette V; Desgranges B; Chételat G Neurobiol Aging; 2018 Mar; 63():140-151. PubMed ID: 29203090 [TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of Braak stage- and APOE4 allele-dependent associations between MR spectroscopy and markers of tau and neurodegeneration in cognitively unimpaired elderly. Chen AM; Gajdošík M; Ahmed W; Ahn S; Babb JS; Blessing EM; Boutajangout A; de Leon MJ; Debure L; Gaggi N; Gajdošík M; George A; Ghuman M; Glodzik L; Harvey P; Juchem C; Marsh K; Peralta R; Rusinek H; Sheriff S; Vedvyas A; Wisniewski T; Zheng H; Osorio R; Kirov II Neuroimage; 2024 Aug; 297():120742. PubMed ID: 39029606 [TBL] [Abstract][Full Text] [Related]
26. A "multi-omics" analysis of blood-brain barrier and synaptic dysfunction in APOE4 mice. Barisano G; Kisler K; Wilkinson B; Nikolakopoulou AM; Sagare AP; Wang Y; Gilliam W; Huuskonen MT; Hung ST; Ichida JK; Gao F; Coba MP; Zlokovic BV J Exp Med; 2022 Nov; 219(11):. PubMed ID: 36040482 [TBL] [Abstract][Full Text] [Related]
27. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Murphy KR; Landau SM; Choudhury KR; Hostage CA; Shpanskaya KS; Sair HI; Petrella JR; Wong TZ; Doraiswamy PM; Neuroimage; 2013 Sep; 78():474-80. PubMed ID: 23624169 [TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529 [TBL] [Abstract][Full Text] [Related]
29. Hippocampal blood-brain barrier permeability is related to the APOE4 mutation status of elderly individuals without dementia. Moon WJ; Lim C; Ha IH; Kim Y; Moon Y; Kim HJ; Han SH J Cereb Blood Flow Metab; 2021 Jun; 41(6):1351-1361. PubMed ID: 32936729 [TBL] [Abstract][Full Text] [Related]
30. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease. Lin AL; Parikh I; Yanckello LM; White RS; Hartz AMS; Taylor CE; McCulloch SD; Thalman SW; Xia M; McCarty K; Ubele M; Head E; Hyder F; Sanganahalli BG Neurobiol Dis; 2020 Jun; 139():104834. PubMed ID: 32173556 [TBL] [Abstract][Full Text] [Related]
31. A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Sweeney MD; Sagare AP; Pachicano M; Harrington MG; Joe E; Chui HC; Schneider LS; Montagne A; Ringman JM; Fagan AM; Morris JC; Pa J; Nation DA; Toga AW; Zlokovic BV Alzheimers Dement; 2020 Jun; 16(6):821-830. PubMed ID: 32301266 [TBL] [Abstract][Full Text] [Related]
32. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4. Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD; JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020 [TBL] [Abstract][Full Text] [Related]
33. Effects of apolipoprotein E4 genotype on cerebro-cerebellar connectivity, brain atrophy, and cognition in patients with Alzheimer's disease. de Dieu Uwisengeyimana J; Wang Y; Nguchu BA; Wang X; Qiu B J Neurol Sci; 2022 Nov; 442():120435. PubMed ID: 36201963 [TBL] [Abstract][Full Text] [Related]
34. Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms. Osorio RS; Pirraglia E; Gumb T; Mantua J; Ayappa I; Williams S; Mosconi L; Glodzik L; de Leon MJ Neurodegener Dis; 2014; 13(2-3):163-5. PubMed ID: 24107601 [TBL] [Abstract][Full Text] [Related]
35. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. van Arendonk J; Neitzel J; Steketee RME; van Assema DME; Vrooman HA; Segbers M; Ikram MA; Vernooij MW Brain; 2023 Jan; 146(1):337-348. PubMed ID: 36374264 [TBL] [Abstract][Full Text] [Related]
36. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815 [TBL] [Abstract][Full Text] [Related]
37. APOE ε4 is associated with decreased synaptic density in cognitively impaired participants. He K; Li B; Wang J; Wang Y; You Z; Chen X; Chen H; Li J; Huang Q; Guo Q; Huang YH; Guan Y; Chen K; Zhao J; Deng Y; Xie F Alzheimers Dement; 2024 May; 20(5):3157-3166. PubMed ID: 38477490 [TBL] [Abstract][Full Text] [Related]
38. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients. Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H; J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397 [TBL] [Abstract][Full Text] [Related]
39. Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease. Lodeiro M; Ibáñez C; Cifuentes A; Simó C; Cedazo-Mínguez Á J Alzheimers Dis; 2014; 41(1):223-32. PubMed ID: 24595197 [TBL] [Abstract][Full Text] [Related]